Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1087057105284576v1
11/2/176    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Henrich, C. J.
Right arrow Articles by McMahon, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henrich, C. J.
Right arrow Articles by McMahon, J. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity

Curtis J. Henrich1*, Heidi R. Bokesch1, Michael Dean2, Susan E. Bates3, Robert W. Robey3, Ekaterina I. Goncharova4, Jennifer A. Wilson5, James B. McMahon5

1 Basic Research Program, SAIC-Frederick, Inc., NCI Frederick, Frederick, MD.; Molecular Targets Development Program, NCI Frederick, Frederick, MD.
2 Laboratory of Genomic Diversity, NCI Frederick, Frederick, MD.
3 Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD.
4 Molecular Targets Development Program, NCI Frederick, Frederick, MD.; Data Management Services, Inc., NCI Frederick, Frederick, MD.
5 Molecular Targets Development Program, NCI Frederick, Frederick, MD.

* To whom correspondence should be addressed. E-mail: henrichc{at}ncifcrf.gov.


   Abstract

ABCG2 is a member of the adenosine triphosphate (ATP)-binding cassette family of multidrug transporters associated with resistance of tumor cells to many cytotoxic agents. Evaluation of modulators of ABCG2 activity has relied on methods such as drug sensitization, biochemical characterization, and transport studies. To search for novel inhibitors of ABCG2, a fluorescent cell-based assay was developed for application in high-throughput screening. Accumulation of pheophorbide a (PhA), an ABCG2-specific substrate, forms the basis for the assay in NCI-H460/MX20 cells overexpressing wild-type ABCG2. Treatment of these cells with 10 µM fumitremorgin C (FTC), a specific ABCG2 inhibitor, increased cell accumulation of PhA to 5.6 times control (Z' 0.5). Validation included confirmation with known ABCG2 inhibitors: FTC, novobiocin, tariquidar, and quercetin. Verapamil, reported to inhibit P-glycoprotein but not ABCG2, had insignificant activity. Screening of a library of 3523 natural products identified 11 compounds with high activity (≥ 50% of FTC, confirmed by reassay), including 3 flavonoids, members of a family of compounds that include ABCG2 inhibitors. One of the inhibitors detected, eupatin, was moderately potent (IC50 of 2.2 µM) and, like FTC, restored sensitivity of resistant cells to mitoxantrone. Application of this assay to other libraries of synthetic compounds and natural products is expected to identify novel inhibitors of ABCG2 activity.

Key Words: ABCG2, pheophorbide a, drug resistance

First published on February 20, 2006, doi:10.1177/1087057105284576

Journal of Biomolecular Screening 2006;11:176.

A more recent version of this article appeared on March 1, 2006


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Zhang, Y. Byun, Y. R. Ren, J. O. Liu, J. Laterra, and M. G. Pomper
Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay
Cancer Res., July 15, 2009; 69(14): 5867 - 5875.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. J. Henrich, R. W. Robey, H. R. Bokesch, S. E. Bates, S. Shukla, S. V. Ambudkar, M. Dean, and J. B. McMahon
New inhibitors of ABCG2 identified by high-throughput screening
Mol. Cancer Ther., December 1, 2007; 6(12): 3271 - 3278.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhang, J. P. Bressler, J. Neal, B. Lal, H.-E. C. Bhang, J. Laterra, and M. G. Pomper
ABCG2/BCRP Expression Modulates D-Luciferin Based Bioluminescence Imaging
Cancer Res., October 1, 2007; 67(19): 9389 - 9397.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
M. Dean
CANCER STEM CELLS: Redefining the Paradigm of Cancer Treatment Strategies
Mol. Interv., June 1, 2006; 6(3): 140 - 148.
[Abstract] [Full Text] [PDF]